News and Events - Cardionovum®

Latest press release

Mar 31, 2021

CARDIONOVUM announces completion of patients enrolment in XLIMIT Trial

Trial designed to evaluate non inferiority of XLIMUS DES vs SYNERGY EES in terms of reendothelialization assessed with OCT in patients undergoing percutaneous coronary intervention

Learn more >> CARDIONOVUM announces completion of patients enrolment in XLIMIT Trial

Jan 24, 2021

Two-year outcomes with the LEGFLOW DCB: primary patency maintained in real world patients.

Marc Bosiers (St. Blasius Hospital, Dendermonde, Belgium) will give an update at LINC today on the results of the REFLOW1 study, which investigated the efficacy of the LEGFLOW® drug-coated balloon (DCB) in TASC C and D femoropopliteal lesions.

Learn more >> Two-year outcomes with the LEGFLOW DCB: primary patency maintained in real world patients.

Jan 17, 2021

APERTO DCB “superior” for AV fistulae lesions in new RCT.

Professor Dr Qizhuang Jin (Peking University First Hospital Nephrology Department, China) spoke to LINC Today about the recently published results of the first randomised controlled trial (RCT) comparing the APERTO® drug-coated balloon (DCB) with high pressure angioplasty balloon in the treatment of arteriovenous fistulae (AVF) lesions.

Learn more >> APERTO DCB “superior” for AV fistulae lesions in new RCT.

Jan 10, 2021

APERTO DCB “promising” for central venous stenosis in haemodialysis patients.

In a Q&A with LINC Today, Michael Lichtenberg, angiologist at Klinikum Hochsauerland GmbH, Arnsberg, Germany, discussed the APERTO® OTW (over-the-wire) drug coated balloon (DCB) currently being trialled in haemodialysis patients with central venous stenosis (CVS) in a bid to improve patency of arteriovenous fistulas (AVFs).

Learn more >> APERTO DCB “promising” for central venous stenosis in haemodialysis patients.

May 09, 2020

Cardionovum - first transcontinental China-Europe Webinar on the treatment of complications in arteriovenous access in dialysis patients during COVID-19 pandemic.

Guest from Europe: Prof. Michael Lichtenberg (Germany) & Prof. Matteo Tozzi (Italy).

Video of European guests' speech.

Learn more >> Cardionovum - first transcontinental China-Europe Webinar on the treatment of complications in arteriovenous access in dialysis patients during COVID-19 pandemic.

Apr 20, 2020

APERTO OTW® Drug Coated Balloon receives first Chinese NMPA Medical Device Registration Certificate for High Pressure DCB for Vascular Access

APERTO®, our innovative paclitaxel coated balloon for arterio-venous access, has received market approval for China. It is the the first high pressure drug coated balloon available in China to treat obstructive lesions of native Arterio Venous Dialysis Fistulae.

The approval was given based on the statistic results from the solidly designed clinical study in Chinese population:
APERTO AVF RCT CHINA.

Learn more >> APERTO OTW® Drug Coated Balloon receives first Chinese NMPA Medical Device Registration Certificate for High Pressure DCB for Vascular Access

Upcoming events

Currently there are no events.

Latest events

Cardionovum at BSIR

Cardionovum participates
together with their partner in the UK;
Aquilant a Health-Care 21 Company
At the BSIR; British Society of Interventional Radiology

You are welcome to visit us at booth Nr. 15

Location: Glasgow, UK

Date: Dec 08, 2021–Dec 10, 2021

New edition of "THE CARDIONOVUM UNIVERSITY"

It is with great pleasure that CARDIONOVUM announces a new edition of “THE CARDIONOVUM UNIVERSITY”.
During this new edition we will concentrate on our Coronary DCB, the RESTORE.

You are kindly invited to participate by clicking here:
https://www.oneviewx.com/event/restore-cardionovum-university-online-webinar/

Date: Dec 03, 2021

CARDIONOVUM GmbH at the Union Conference

Cardionovum participates in:
21st Union Conference of the Swiss Society for Vascular Diseases

You are cordially invited to visit us at booth no.38.

Location: Interlaken, Switzerland

Date: Dec 01, 2021–Dec 03, 2021

CARDIONOVUM GmbH at IAD

Cardionovum participates in:
9th Annual IAD Conference Interdisciplinary Working Group on Dialysis Access.

We invite you to visit us at booth #7.

Location: Weimar, Germany

Date: Nov 19, 2021–Nov 20, 2021

Cardionovum at CIRSE 2021 Cardionovum at CIRSE 2021

Cardionovum invites you to participate in 3 scientific presentations in the "Technology Innovations Videos":

Sunday 26th
The SAFEPAX Technology presented by Dr. Michael Lichtenberg.
Monday 27th
The Reflow Study at 2 years follow up. by Dr. Marc Bosiers.
Tuesday 28th
Clinical outcomes with APERTO Balloon. by Dr. Matteo Tozzi.

Date: Sep 25, 2021–Sep 28, 2021

Cardionovum at CIRSE 2021 Learn more >>

Cardionovum at EuroPCR 18, 19, 20 May 2021 Cardionovum at EuroPCR 18, 19, 20 May 2021

Cardionovum invites you to participate in on demand interviwes:

XLIMIT Trial RCT, with Dr. Luca Testa from Italy.
Goal: to assess angiographic and clinical performance of the Xlimus Biodegradable Polymer Sirolumus-eluting stent versus a gold standard like Synergy Biodegradable Polymer Everolimus Stent in patients treated with percutaneous coronary angioplasty.
Hyper Registry with Dr. Alfonso Ileasi from Italy.
Goal: Asses the clinical results after a Hybrid Approach in diffuse CAD lesions longer tan 28mm combinig Restore DCB and New generation DES.

Date: May 18, 2021–May 20, 2021

Cardionovum at EuroPCR 18, 19, 20 May 2021 Learn more >>

Cardionovum - Meeting & Symposium at LINC 2020 Cardionovum - Meeting & Symposium at LINC 2020

Cardionovum participates at LINC
Leipzig Interventional Course
You are welcome to visit us at booth no. 19 c

Date: Jan 28, 2020–Jan 31, 2020

Location: Leipzig, Germany

Cardionovum - Meeting & Symposium at LINC 2020 Learn more >>

Be up to date.

Latest press release

Upcoming events

Latest events

Cardionovum at BSIR

New edition of "THE CARDIONOVUM UNIVERSITY"

CARDIONOVUM GmbH at the Union Conference

CARDIONOVUM GmbH at IAD

Cardionovum at EuroPCR

Cardionovum at CIRSE

Cardionovum at CIRSE annual meeting

Cardionovum at CIRSE

Cardionovum at EuroPCR

Cardionovum at Charing Cross

Be up
to date.